Market Cap
US$460.6m
Last Updated
2019/12/08 01:05 UTC
Data Sources
Company Financials +
Executive Summary
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States.
Rewards
Risk Analysis
Snowflake Analysis
High growth potential and slightly overvalued.
Share Price & News
How has Evolus's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: EOLS's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-10.7%
EOLS
1.5%
US Pharmaceuticals
0.03%
US Market
1 Year Return
-9.1%
EOLS
-0.1%
US Pharmaceuticals
18.6%
US Market
Return vs Industry: EOLS underperformed the US Pharmaceuticals industry which returned -0.1% over the past year.
Return vs Market: EOLS underperformed the US Market which returned 18.6% over the past year.
Shareholder returns
| EOLS | Industry | Market | |
|---|---|---|---|
| 7 Day | -10.7% | 1.5% | 0.03% |
| 30 Day | -12.2% | -1.0% | 1.7% |
| 90 Day | -18.5% | 7.7% | 5.7% |
| 1 Year | -9.1%-9.1% | 2.5%-0.1% | 21.1%18.6% |
| 3 Year | n/a | 31.3%21.9% | 45.6%36.2% |
| 5 Year | n/a | 25.8%12.5% | 71.1%52.3% |
Price Volatility Vs. Market
How volatile is Evolus's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall St
Market Sentiment Around Loss-Making Evolus, Inc. (NASDAQ:EOLS)2 months ago | Simply Wall St
Those Who Purchased Evolus (NASDAQ:EOLS) Shares A Year Ago Have A 13% Loss To Show For It3 months ago | Simply Wall St
How Much Are Evolus, Inc. (NASDAQ:EOLS) Insiders Spending On Buying Shares?Valuation
Is Evolus undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: EOLS ($12.5) is trading below our estimate of fair value ($72.26)
Significantly Below Fair Value: EOLS is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: EOLS is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.
PE vs Market: EOLS is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate EOLS's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: EOLS is overvalued based on its PB Ratio (20.1x) compared to the US Pharmaceuticals industry average (3.1x).
Next Steps
Future Growth
How is Evolus forecast to perform in the next 1 to 3 years based on estimates from 8 analysts?
67.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EOLS is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: EOLS is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: EOLS's is expected to become profitable in the next 3 years.
Revenue vs Market: EOLS's revenue (45.8% per year) is forecast to grow faster than the US market (7.4% per year).
High Growth Revenue: EOLS's revenue (45.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if EOLS's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Evolus performed over the past 5 years?
-49.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: EOLS is currently unprofitable.
Growing Profit Margin: EOLS is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: EOLS is unprofitable, and losses have increased over the past 5 years at a rate of -49.1% per year.
Accelerating Growth: Unable to compare EOLS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: EOLS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (21.3%).
Return on Equity
High ROE: EOLS has a negative Return on Equity (-516.15%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Evolus's financial position?
Financial Position Analysis
Short Term Liabilities: EOLS's short term assets ($95.2M) exceed its short term liabilities ($26.0M).
Long Term Liabilities: EOLS's short term assets ($95.2M) do not cover its long term liabilities ($139.6M).
Debt to Equity History and Analysis
Debt Level: EOLS's debt to equity ratio (429.4%) is considered high.
Reducing Debt: Insufficient data to determine if EOLS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: EOLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: EOLS's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EOLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EOLS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Evolus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate EOLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EOLS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EOLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EOLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EOLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
What is the CEO of Evolus's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
David Moatazedi (41yo)
1.6yrs
Tenure
US$5,794,178
Compensation
Mr. David Moatazedi has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Moatazedi served as Senior Vice President of Medical Aesthetics at Alle ...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD5.79M) is above average for companies of similar size in the US market ($USD1.71M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
Management Age and Tenure
1.3yrs
Average Tenure
49yo
Average Age
Experienced Management: EOLS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
1.9yrs
Average Tenure
55.5yo
Average Age
Experienced Board: EOLS's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,000 |
| Max Price | US$13.65 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 1,298,701 |
| Max Price | US$19.25 |
| Entity | Company |
| Shares | 1,298,701 |
| Max Price | US$19.25 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 2,090 |
| Max Price | US$14.77 |
| Entity | Individual |
| Role | Chief Financial Officer CFO & Executive VP of Corporate Development |
| Shares | 2,612 |
| Max Price | US$13.53 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 40,562 |
| Max Price | US$19.25 |
| Entity | Individual |
| Role | Member of the Board of Directors Director |
| Shares | 628,536 |
| Max Price | US$19.25 |
| Entity | Company |
| Shares | 5,307,940 |
| Max Price | US$19.25 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 16,000 |
| Max Price | US$12.75 |
| Entity | Individual |
| Role | Member of the Board of Directors Independent Director |
| Shares | 3,000 |
| Max Price | US$12.77 |
| Entity | Individual |
| Role | Chairman of the Board Chairman of the Board |
| Shares | 7,800 |
| Max Price | US$13.04 |
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.
Management Team
Lauren Silvernail (60yo)
CFO & Executive VP of Corporate Development
- Tenure: 1.6yrs
- Compensation: US$3.83m
David Moatazedi (41yo)
President
- Tenure: 1.6yrs
- Compensation: US$5.79m
Rui Avelar (57yo)
Chief Medical Officer and Head of Research & Development
- Tenure: 5.9yrs
- Compensation: US$365.00k
Jeff Plumer
Vice President of Legal
- Tenure: 0yrs
Mike Jafar (38yo)
Chief Marketing Officer
- Tenure: 1.5yrs
- Compensation: US$3.93m
Ashwin Agarwal
Vice President of Finance
- Tenure: 1.3yrs
Kurt Knab
President of Sales
- Tenure: 1.2yrs
Alex Sabad
Vice President of Operations
- Tenure: 1.2yrs
Amy Fox
Vice President of Human Resources
- Tenure: 1.2yrs
Crystal Muilenburg
Vice President of Corporate Communications & Public Relations
- Tenure: 0.8yrs
Board Members
Peter Farrell (77yo)
Independent Director
- Tenure: 0.4yrs
David Gill (64yo)
Independent Director
- Tenure: 1.8yrs
- Compensation: US$148.41k
Simone Blank (55yo)
Director
- Tenure: 1.9yrs
- Compensation: US$154.49k
Bosun Hau
Independent Director
- Tenure: 1.9yrs
- Compensation: US$154.49k
Robert Hayman (60yo)
Independent Director
- Tenure: 1.9yrs
- Compensation: US$150.07k
Vik Malik (56yo)
Chairman of the Board
- Tenure: 1.9yrs
- Compensation: US$158.90k
Karah Parschauer (41yo)
Independent Director
- Tenure: 0.4yrs
David Moatazedi (41yo)
President
- Tenure: 1.6yrs
- Compensation: US$5.79m
Kristine Romine (54yo)
Independent Director
- Tenure: 1.9yrs
- Compensation: US$150.07k
Company Information
Evolus, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Evolus, Inc.
- Ticker: EOLS
- Exchange: NasdaqGM
- Founded: 2012
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$460.593m
- Shares outstanding: 33.42m
- Website: https://www.evolus.com
Number of Employees
Location
- Evolus, Inc.
- 520 Newport Center Drive
- Suite 1200
- Newport Beach
- California
- 92660
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| EOLS | NasdaqGM (Nasdaq Global Market) | Yes | Common Stock | US | USD | Feb 2018 |
| EVL | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Feb 2018 |
| 0K16 | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Feb 2018 |
Biography
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum to ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/12/08 01:05 |
| End of Day Share Price | 2019/12/06 00:00 |
| Earnings | 2019/09/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.